Hematologic Oncology Articles

KD025 Hits High Response Rate in Chronic GVHD
Treatment with the selective ROCK2 inhibitor KD025 led to statistically significant overall response rates in patients with chronic graft-versus-host disease who have received ≥2 prior lines of systemic therapy.
Investigators Link Novel Biomarker to Therapy in DLBCL Trial
Investigators are exploring the novel genetic biomarker DGM1 as a potential predictor of benefit from the experimental agent enzastaurin in treatment-naïve patients with high-risk diffuse large B-cell lymphoma.
The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
Ixazomib Improves PFS as Frontline Maintenance in Multiple Myeloma
Ixazomib significantly improved progression-free survival as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.
Novel Combinations Could Improve Cure Rates for Adult ALL
Novel combinations of biologic therapies, third-generation TKIs, and chemotherapy could lead to significantly higher cure rates for adult patients with acute lymphoblastic leukemia, with a number of early stage studies already showing promising results, according to Hagop M. Kantarjian, MD, at the 37th Annual CFS®.
Expert Explains Treatment Considerations in Newly Diagnosed Follicular Lymphoma
Given that a watch-and-wait approach is a viable option, clinicians must carefully consider disease characteristics when selecting a treatment strategy in newly diagnosed follicular lymphoma.
New Sequencing Approaches Shape Follicular Lymphoma Landscape
With a variety of available agents in follicular lymphoma, determining which treatments to choose and how best to sequence them can be challenging. 
Gilteritinib demonstrated a higher remission rate and a statistically significant improvement in overall survival compared with salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia who harbor a FLT3 mutation.
Umbralisib Hits Primary Endpoint in Follicular Lymphoma Subgroup of Pivotal Study
Umbralisib (TGR-1202) met the primary endpoint of overall response rate in the follicular lymphoma cohort of the pivotal phase IIb UNITY-NHL trial, according to TG Therapeutics, Inc., the developer of the PI3K-delta inhibitor.
Iomab-B Leads to High Bone Marrow Transplant Rate in Relapsed/Refractory AML
Treatment with iodine-131 apamistamab led to a high bone marrow transplant rate compared with salvage chemotherapy in elderly patients with relapsed/refractory acute myeloid leukemia.
Publication Bottom Border
Border Publication